• Subscribe
  • Newsfeed
  • About
  • Jobs
AI Search
Announce News

LifeArc Ventures: Investment Portfolio & Startup News

LifeArc Ventures

To add a bio or update investment portfolio click update information.

Investment Portfolio

    RQ Bio raises a £86m Series A led by Frazier Life Sciences to develop long-acting antibody protection against seasonal influenzaRQ Bio raises a £86m Series A led by Frazier Life Sciences to develop long-acting antibody protection against seasonal influenza
    RQ Bio
    25 Jun 2026

    RQ Bio raises a £86m Series A led by Frazier Life Sciences to develop long-acting antibody protection against seasonal influenza

    RQ Bio is a UK-based biotechnology company developing long-acting monoclonal antibodies against seasonal influenza. Its lead programme, RQB01, is designed to deliver potent, broad-strain protection against influenza through a dual mechanism of action, targeting patients whose immune systems cannot rely on vaccination alone.

    Cytospire Therapeutics secures £61m Series A led by 4BIO Capital for cancer therapies that activate the body’s immune cellsCytospire Therapeutics secures £61m Series A led by 4BIO Capital for cancer therapies that activate the body’s immune cells
    Cytospire Therapeutics
    5 May 2026

    Cytospire Therapeutics secures £61m Series A led by 4BIO Capital for cancer therapies that activate the body’s immune cells

    Cytospire Therapeutics develops multispecific immune cell engager antibodies designed to enhance and direct the activity of the body’s immune system. Its platform targets gamma delta T cells to generate anti tumour immune responses for patients with cancer and other diseases.

LifeArc Ventures
    • Life Sciences
  • 2(12 months)
  • lifearc.org/early-ventures

More venture news

  • Oyster Therapeutics secures a £45m Series A round from CE-Ventures to develop an oral drug for neurodegenerative diseases
    Oyster Therapeutics
    13 Nov 2026

    Oyster Therapeutics secures a £45m Series A round from CE-Ventures to develop an oral drug for neurodegenerative diseases

    Series ALife Sciences
  • UFORCE secures a £530m Series A round led by Valor Equity Partners and UK National Wealth Fund to build uncrewed defence platforms
    UFORCE
    12 Nov 2026

    UFORCE secures a £530m Series A round led by Valor Equity Partners and UK National Wealth Fund to build uncrewed defence platforms

    Series ADefence
  • FluoRok closes a £22m Series A round led by Orano and Supernova to manufacture safer fluorochemicals for lithium-ion batteries
    FluoRok
    5 Nov 2026

    FluoRok closes a £22m Series A round led by Orano and Supernova to manufacture safer fluorochemicals for lithium-ion batteries

    Series AIndustrial

Sign-up to our newsletter

The UK Weekly email covers every VC round from last week, firms that are hiring, and much more

Soapbox Ventures Limited © 2026

Disclaimer

Privacy Policy

LinkedIn

Announce

  • Share your story

General

  • Read the latest
  • About Soapbox

Information not up to date?

Get in touch

Soapbox Ventures Limited © 2026

Disclaimer

Privacy Policy

LinkedIn